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Primary eosinophilic gastrointestinal disorders (EGIDs),
including eosinophilic esophagitis (EoE) and eosinophilic gastroen-
teritis (EGE), exclusively affect the gastrointestinal tract with
eosinophil-predominant inﬂammation, where gastrointestinal
eosinophilia secondary to other diseases, such as drug-induced
and parasitic disorders, have been excluded.1 In addition, EoE occa-
sionally occurs secondary to EGE.
As recently suggested in U.S. guidelines for EoE,2,3 when EoE
suspected by clinical and pathological ﬁndings responds well to
proton-pump inhibitors (PPIs), it is distinguished from typical EoE
as a newly recognized entity known as PPI-responsive esophageal
eosinophilia (EE) (PPI-REE). Therefore, PPI trials using high-dose
PPIs are recommended as a ﬁrst-line therapy or diagnostic tool to
distinguish PPI-REE from EoE. The effect of PPIs for gastrointestinal
eosinophilia, except for PPI-REE, remain unknown. Here, we report
a case of EGE associated with duodenal and esophageal eosino-
philia successfully treated with a PPI.
Case report
A 2-year and 7-month-old girl underwent upper gastrointes-
tinal endoscopic examination at our hospital for a follow-up. She
had been diagnosed with EGID associated with duodenal eosino-
phil inﬁltration at 11 months of age.4 Elemental diet (ED) caused
rapid weight gain and improved tracheal aspiration and esophageal
clearance, but duodenal eosinophil inﬁltration persisted. The exac-
erbation of symptoms was not observed, and the ED was replaced
with enteral formula, although she required the tubing of enteral
formula because of difﬁculty in or reluctance to oral intake.
On upper gastrointestinal endoscopic examination, biopsies
showed EE that had not been previously detected and persistent
duodenal eosinophil inﬁltration with 106 eosinophils/high power
ﬁeld (HPF) and 72 eosinophils/HPF, respectively (Fig. 1A, B, respec-
tively). According to the U.S. guideline for EoE,2,3 a PPI trial using
oral lansoprazole (up to 30 mg/day) was begun in a subsequent
clinic visit to determine her response. After PPI-treatment initia-
tion, the patient's appetite improved, and subsequently, her
amount of oral food intake increased gradually. Five months after
starting PPI treatment, tube feeding was discontinued, and reeval-
uation of upper endoscopy was concurrently performed for patho-
logical evaluation after PPI treatment. Duodenal eosinophilia and
EE detected in the prior examination had drastically improvedPeer review under responsibility of Japanese Society of Allergology.
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amounts of a variety of foods. Eight months after terminating
tube feeding, PPI was tapered and discontinued. At the time of
reporting this case, she remains symptom-free with a regular diet
and no PPI treatment.
Discussion
Although a recent report showed that PPI-REE possesses signif-
icant molecular overlap with EoE,5 it remains to be determined if
PPI-REE represents a subtype of EoE, a gastroesophageal reﬂux
disease-associated condition, or a unique entity. In addition, the
possible mechanisms of PPI action in EE5 may be a direct anti-
inﬂammatory effect via blockade of IL-4e and IL-13estimulated
secretion of eotaxin-36 and healing of disrupted epithelium as
well as acid suppression, which may shorten eosinophil viability
by increasing pH. Indeed, this patient's pH monitoring at ﬁrst
admission was negative. Taken together, although EE secondary
to EGEmay be much different from the conditions described above,
PPI appears to be a promising treatment for this condition. In the
present case, during the initial treatment, ED did not lead to com-
plete remission, whereas PPI completely improved both clinical
and histological ﬁndings. More surprisingly, the duodenal as well
as esophageal eosinophil inﬁltrations nearly disappeared.
Duodenal eosinophilia in this patient had never been improved
well before. This may suggest that PPI also blocks the activation
of STAT6 directly by IL-4 and IL-13 in the duodenal epithelium,
since this inhibitory effect is not speciﬁc for esophageal epithelium
and may be observed in many other cell lines.7 Measurements of
gastrointestinal cytokine levels (such as with the string test) and
pH in peri-PPI trials may be also important in revealing
mechanisms.
A PPI trial may be the only way to distinguish PPI-REE from EoE
because of their clinical and histological similarity. Therefore, the
long-term prognosis of PPI-REE could vary. PPI alone may not be
sufﬁcient to induce complete remission; combining PPI with prior
ED treatment might be required. Additionally, there is a possibility
that ED did not induce complete remission due to other inﬂamma-
tory conditions, such as Helicobacter pylori infection, as well as al-
lergy, although the patient's allergy status was unclear. In order
to dissect these mechanisms, allergy tests, such as the allergen-
speciﬁc lymphocyte stimulation test and pylorus infection test,
should be performed if the patient's EGIDs recur.
Two major treatments for EGE are considered in most cases.1
One is the use of corticosteroids such as prednisolone. Additionally,
especially in children, dietary eliminations have often been chosenvier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
Fig. 1. Histological ﬁndings of esophagus and duodenum stained with H.E. before and after PPI-treatment. (A) Esophageal and (B) duodenal eosinophil inﬁltrations with 106 eo-
sinophils/high power ﬁeld (HPF) and 72 eosinophils/HPF respectively, are shown in pretreatment biopsies. (C) and (D) indicate esophagus with 1 eosinophil/HPF and duodenum
with 3 eosinophils/HPF after PPI-treatment, respectively (Original optical magniﬁcations: 200 in all ﬁgures).
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unknown or the effects of their elimination are restricted, amino
acid-based EDs are used, often resulting in complete remission.1
Therefore, ED was initially used, and the response was favorable
in this case. However, difﬁculty in or reluctance to oral intake
that may be associated with EGID4 and tissue eosinophilia
remained, and our patient showed the ﬁrst signs of improvement
of them with PPI treatment, suggesting that PPI could promise a
certain level of additive or synergistic effect with ED or dietary
modiﬁcations.
Only nonspeciﬁc inﬂammation had been observed in her esoph-
agus before. Usually, more than three esophageal biopsies are taken
evenly from the proximal to distal esophagus in our hospital.
Consequently, it is unlikely that we missed EE. EE can be a part of
the ﬁndings of EGE and discovered during the course of EGE. Inter-
estingly, there are previous reports of unusual cases of EGE in pa-
tients who had eosinophil inﬁltration, preferentially not in the
epithelium but in the deep mucosal and submucosal layers of the
esophagus9 or gastric muscularis,10 meaning that esophageal eosin-
ophil inﬁltration can sometimes be primarily observed in places
other than the superﬁcial mucosa.
In conclusion, we describe a patient with an initial diagnosis of
EGID with duodenal eosinophilic inﬁltration who developed EE
during follow-up. PPI treatment used for the concurrent EE unex-
pectedly resulted in eradicating the duodenal eosinophilia as well
as the EE, and overall symptomatic improvement was also
observed. PPI treatment can be a promising additive approach
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